-1.05%
-0.19%
7.27%
17.12%
-7.95%
-33.15%
-1.17%
AI Spotlight on EW
Company Description
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally.It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy.
In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation.Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure.The company distributes its products through a direct sales force and independent distributors.
Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Market Data
| Last Price | 72.45 |
| Change Percentage | -1.05% |
| Open | 73.33 |
| Previous Close | 73.22 |
| Market Cap ( Millions) | 42731 |
| Volume | 1944510 |
| Year High | 96.12 |
| Year Low | 58.93 |
| M A 50 | 71.95 |
| M A 200 | 75.79 |
Financial Ratios
| FCF Yield | 1.18% |
| Dividend Yield | 0.00% |
| ROE | 54.10% |
| Debt / Equity | 7.40% |
| Net Debt / EBIDTA | -174.42% |
| Price To Book | 4.53 |
| Price Earnings Ratio | 10.4 |
| Price To FCF | 85.09 |
| Price To sales | 7.28 |
| EV / EBITDA | 23.35 |
News
- Jan -30 - Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion
- Jan -30 - Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth
- Jan -16 - Should Edwards Lifesciences Stock Stay in Your Portfolio Now?
- Jan -16 - Wedgewood Partners: Q4 And 2024 Top Performers And Detractors
- Jan -07 - Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -30 - 4 Strong Stock Charts For 2025 (Technical Analysis)
- Dec -20 - Is the Options Market Predicting a Spike in Edwards (EW) Stock?
- Dec -13 - Investors who lost money on Edwards Lifesciences Corporation (EW) should contact Levi & Korsinsky about pending Class Action - EW
- Dec -13 - EW DEADLINE TODAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class Action – EW
- Dec -13 - Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?
- Dec -13 - FINAL REMINDER EW DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Edwards Lifesciences Corporation Investors to Participate in the Class Action Lawsuit
- Dec -13 - Levi & Korsinsky Reminds Edwards Lifesciences Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 - EW
- Dec -12 - EW INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- Dec -12 - EW FINAL DEADLINE FRIDAY: Edwards Lifesciences Investors have Until Tomorrow December 13 before Expiration of Court Deadline - Contact BFA Law
- Dec -12 - The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Edwards Lifesciences Corporation (EW)
- Dec -12 - EW Deadline in 1 Days: Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifesciences Corporation (EW) Investors of Filing Deadline in Class Action Lawsuit
- Dec -12 - DEADLINE TOMORROW: Edwards Lifesciences Corporation Is Being Sued For Violating Securities Laws And The Schall Law Firm Urges Affected Shareholders To Reach Out
- Dec -12 - EW COURT DEADLINE TOMORROW: BFA Law Alerts Edwards Lifesciences Investors of Tomorrow's December 13 Securities Fraud Class Action Deadline (NYSE:EW)
- Dec -12 - FINAL EW DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Edwards Lifesciences Corporation. Investors to Join the Class Action Lawsuit
- Dec -12 - Shareholders that lost money on Edwards Lifesciences Corporation(EW) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Transcatheter Aortic Valve Replacement
Expected Growth : 12 %
What the company do ?
Why we expect these perspectives ?
Strong demand for minimally invasive procedures, increasing adoption in low-risk patients, and expanding indications for TAVR therapy drive growth. Edwards' leadership in the TAVR market, paired with its innovative valve designs and strong clinical outcomes, further support the 12% growth rate.
Segment n°2 -> Surgical Heart Valve Therapy
Expected Growth : 8 %
What the company do ?
Why we expect these perspectives ?
Edwards Lifesciences' Surgical Heart Valve Therapy growth is driven by increasing demand for minimally invasive procedures, advancements in transcatheter valve technologies, and expanding adoption in emerging markets. Additionally, growing prevalence of heart valve diseases, aging population, and increasing healthcare expenditure contribute to the 8% growth rate.
Segment n°3 -> Critical Care
Expected Growth : 7 %
What the company do ?
Why we expect these perspectives ?
Critical Care from Edwards Lifesciences Corporation is driven by increasing adoption of minimally invasive procedures, growing demand for hemodynamic monitoring systems, and expansion into emerging markets. Additionally, advancements in sensor technologies and integration with digital health platforms contribute to the 7% growth rate.
Segment n°4 -> Transcatheter Mitral and Tricuspid Therapies
Expected Growth : 11 %
What the company do ?
Why we expect these perspectives ?
Strong demand for minimally invasive heart valve therapies, increasing adoption of transcatheter mitral and tricuspid therapies, growing prevalence of mitral regurgitation and tricuspid regurgitation, expanding indications and clinical trials, and strategic investments in R&D and commercialization efforts drive the 11% growth of Edwards Lifesciences' Transcatheter Mitral and Tricuspid Therapies segment.
Edwards Lifesciences Corporation Products
| Product Range | What is it ? |
|---|---|
| Transcatheter Heart Valves | Edwards Lifesciences offers a range of transcatheter heart valves, including the SAPIEN 3 and SAPIEN 3 Ultra valves, which are designed to treat aortic stenosis and other heart valve diseases. |
| Surgical Heart Valves | The company's surgical heart valves, such as the PERIMOUNT and INTUITY valves, are designed for open-heart surgery to replace diseased or damaged heart valves. |
| Critical Care | Edwards Lifesciences' critical care products, including the FloTrac and EV1000 systems, are designed to monitor and manage cardiovascular and hemodynamic parameters in critically ill patients. |
| Peripheral Vascular | The company's peripheral vascular products, such as the INCRAFT and LIFESTREAM stent grafts, are designed to treat peripheral artery disease and other vascular conditions. |
Edwards Lifesciences Corporation's Porter Forces
Threat Of Substitutes
Edwards Lifesciences Corporation faces moderate threat from substitutes, as there are limited alternatives to its medical devices and technologies. However, the company's focus on innovation and R&D helps it stay ahead of potential substitutes.
Bargaining Power Of Customers
The bargaining power of customers is low for Edwards Lifesciences Corporation, as the company's products are often critical to patient care and hospitals have limited negotiating power. Additionally, the company's strong relationships with healthcare providers help maintain customer loyalty.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate for Edwards Lifesciences Corporation, as the company relies on a diverse range of suppliers for raw materials and components. However, the company's scale and global presence help mitigate supplier power.
Threat Of New Entrants
The threat of new entrants is low for Edwards Lifesciences Corporation, as the medical device industry is highly regulated and requires significant investment in R&D and clinical trials. Barriers to entry are high, and the company's established brand and reputation provide a competitive advantage.
Intensity Of Rivalry
The intensity of rivalry is high for Edwards Lifesciences Corporation, as the medical device industry is highly competitive and fragmented. The company faces intense competition from established players and new entrants, and must continually innovate and invest in R&D to maintain its market position.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 9.46% |
| Debt Cost | 4.24% |
| Equity Weight | 90.54% |
| Equity Cost | 9.57% |
| WACC | 9.06% |
| Leverage | 10.45% |
Edwards Lifesciences Corporation : Quality Control
Edwards Lifesciences Corporation passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| BSX | Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company … |
| DXCM | DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems … |
| ABT | Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. … |
| SYK | Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use … |
| JNJ | Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
J&J
A-Score
1-Year Total Return ->
🥈
Abbott
A-Score
1-Year Total Return ->
🥉
Stryker
A-Score
1-Year Total Return ->
4
Boston Scientific
A-Score
1-Year Total Return ->
5
Edwards Lifesciences
A-Score
1-Year Total Return ->
6
